DONGFENG GROUP
00489
CHINA SHENHUA
01088
CHINA COAL
01898
PETROCHINA
00857
CHINAHONGQIAO
01378
HK Stock MarketDetailed Quotes
02196 FOSUN PHARMA
- 14.260
- -0.160-1.11%
Market Closed Dec 4 16:08 CST
38.00BMarket Cap16.11P/E (TTM)
14.420High14.220Low1.10MVolume14.400Open14.420Pre Close15.68MTurnover0.20%Turnover Ratio14.36P/E (Static)2.66BShares19.50052wk High0.72P/B7.78BFloat Cap11.02052wk Low0.30Dividend TTM545.61MShs Float80.580Historical High0.301Dividend LFY1.39%Amplitude5.897Historical Low14.279Avg Price500Lot Size2.11%Div YieldTTM2.11%Div Yield LFY
FOSUN PHARMA News
Fosun Pharma (02196): Henlius has received approval from the National Medical Products Administration to conduct clinical trials for HLX22 in combination with trastuzumab and chemotherapy or trastuzumab in combination with chemotherapy for HER2-expressing
Fosun Pharma (02196) announced that its controlled subsidiary Henlius Biotech Co., Ltd. and...
Fosun pharma (600196.SH): Approval of clinical trial for injectable HLX43 pharmaceutical.
On December 4th, Gelonghui reported that Fosun Pharma (600196.SH) announced that its controlled subsidiary Henlius Biotechnology Co., Ltd. and its controlled subsidiaries (hereinafter referred to as "Henlius") recently received approval from the National Medical Products Administration to conduct phase Ib/II clinical trials for HLX43 (a targeted PD-L1 antibody-novel DNA topoisomerase I inhibitor conjugate, hereinafter referred to as "the new drug") as a monotherapy or in combination for the treatment of advanced/metastatic solid tumors. Henlius plans to carry out this in china (excluding Hong Kong, Macau, and Taiwan) once conditions are met.
Shanghai Fosun Pharmaceutical (Group)'s Blood Health Medication Gets NMPA's Nod
Fosun Pharma (02196) has had 20 million shares released from pledge by its controlling shareholder, Fosun High Technology.
Fosun Pharma (02196) announced that on December 3, 2024, the company received a notification from its controlling shareholder Fosun...
Fosun Pharma (02196.HK) subsidiary obtained pharmaceutical registration approval.
On December 3, Gelonghui reported that fosun pharma (02196.HK) announced that shanghai fosun pharma (Group) Co., Ltd. (hereinafter referred to as "the company") and shanghai henlius biotechnology Co., Ltd. and its holding subsidiaries (hereinafter collectively referred to as "henlius") have developed the Hanshuang (i.e., Shruvalumab injection, hereinafter referred to as "the pharmaceutical") combined with pemetrexed and carboplatin for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative that cannot be surgically removed.
fosun pharma (600196.SH): Taohong Siwu Granule has received the acceptance of pharmaceutical registration application.
Gelonghui December 3 | fosun pharma (600196.SH) announced that its holding subsidiary Hebei Wanbang Fulin Pharmaceutical Co., Ltd. recently had the pharmaceutical registration application for Taohong Siwu Granules accepted by the National Medical Products Administration. This new drug is a Class 3 traditional chinese medicine, mainly used for nourishing blood, promoting blood circulation, and removing blood stasis, intended for the syndrome of blood deficiency and blood stasis, with symptoms such as irregular menstruation, blood clots, sticky purple complexion, abdominal pain, and bloating. The prescription of this new drug is based on the Taohong Siwu Decoction from the Qing Dynasty's Chai Dehua's "Gynecology Ice Mirror", and has been included in the first batch of the "Catalog of Ancient Classic Prescriptions" by the State Administration of traditional chinese medicine.
Market bullish stimulus boosts Hong Kong pharmaceutical stocks, with Genshuo Niaoyao rising over 14%.
① What bullish impacts does the medical insurance centralized procurement have on pharmaceutical companies? ② How do institutions view the subsequent development of pharmaceutical stocks?
China Securities Co.,Ltd.: In the 2024 version of the medical insurance catalog, the number of innovative drugs added has reached a new high, balancing 'ensuring basic coverage' and 'supporting genuine innovation'.
Overall situation of the 2024 medical insurance catalog: the results are stable, meeting expectations, with a record high in the number of new innovative drugs, reflecting a balanced consideration of fund safety, public medical needs, and support for innovation.
Shanghai Fosun Pharmaceutical (Group) Unit's Cervical Dystonia Gets NMPA Nod
Fosun Pharma Gets Marketing Authorization for Botox Injection
Fosun Pharma Gains Approval for New Drug in China
Fosun Pharma (02196) announced that its major shareholder Fosun Technology has released the pledge of 0.12 billion shares.
Fosun Pharma (02196) announced that it received a notification from its controlling shareholder on November 27, 2024...
Express News | Shanghai Fosun Pharma - Nda of Botulinum Toxin Type a for Injection Approved by Nmpa
Fosun Pharma (02196.HK) spent HKD 4.1039 million on November 27 to repurchase 0.2875 million shares.
Gelonghui reported on November 27 that fosun pharma (02196.HK) announced that on November 27, 2024, it spent 4.1039 million Hong Kong dollars to repurchase 0.2875 million shares, with a repurchase price of 14.06-14.44 Hong Kong dollars per share.
fosun pharma (600196.SH): Licensed products obtain pharmaceutical registration approval.
On November 27, Gelonghui reported that Fosun Pharma (600196.SH) announced that its holding subsidiary Shanghai Fosun Pharma Industrial Development Co., Ltd. has received approval from the National Medical Products Administration for the marketing authorization application of injectable type A botulinum toxin (trademark in China: Daxifei, project code: RT002) for the treatment of adult cervical dystonia.
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Can Mixed Fundamentals Have A Negative Impact on Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) Current Share Price Momentum?
Hong Kong stocks concept tracking | The commercialization trend of surgical siasun robot&automation is obvious, and the prospect of domestic substitution is broad (with concept stocks)
Over 30,000 kilometers, the siasun robot&automation's remote surgery in china once again achieved a breakthrough.
Hong Kong stocks are moving differently | Most pharmaceutical stocks are rising as the results of the medical insurance negotiations are about to be revealed. Institutions indicate that the sector still has further room for recovery.
Most pharmaceutical stocks are rising, as of the deadline, Keji Pharmaceutical-B (02171) rose by 12.38%, to 7.71 Hong Kong dollars; innocare (09969) rose by 5.36%, to 6.49 Hong Kong dollars; Kainuo Ya-B (02162) rose by 4.3%, to 41.25 Hong Kong dollars.
Fosun pharma (02196.HK) spent 1.8 million HKD to repurchase 128,000 shares on November 25.
On November 25th, Gelonhui announced that fosun pharma (02196.HK) issued a notice to repurchase 0.128 million shares for 1.8 million Hong Kong dollars on November 25, 2024, at a repurchase price of 14-14.1 Hong Kong dollars per share.
